You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
Investigators plan to tap into large genomic and other datasets with an in silico patient to simulate drug responses, uncover treatment targets, and assess therapies.
An analysis of pediatric cancer survivors suggests subsequent neoplasm risk can increase after certain genotoxic treatments in those with DNA repair gene changes.
The study will compare whole-genome sequencing and RNA sequencing to conventional diagnostic methods in about 450 acute leukemia patients in Sweden.
The team envisions developing an assay to guide targeted treatment for metastatic castration-resistant prostate cancer patients.
Members of a large, international consortium tapped into whole-genome sequences from nearly 2,700 tumors to explore coding and non-coding variants contributing to cancer.
Tumor genomes from almost 2,400 patients with metastatic cancer revealed a range of somatic alterations, providing a foundation for clinical sequencing efforts.
Though some experts prefer the comprehensive nature of whole-genome sequencing, others find whole-exome sequencing or targeted exome panels to be more useful.
A New York Genome Consortium-led team plans retrospective and prospective analyses on very rare cancers in the hopes of improving treatment options available for patients.
Cancer Moonshot-funded teams are profiling pre-cancers in an effort to establish targeted treatment, detection, and prevention methods that can be applied before cancers form.
A CTC and ctDNA analysis suggests that the number of alterations affecting the androgen receptor can offer survival insights for TP53 mutation-free advanced cancer cases.